ADVFN Logo ADVFN

We could not find any results for:
Make sure your spelling is correct or try broadening your search.

Trending Now

Toplists

It looks like you aren't logged in.
Click the button below to log in and view your recent history.

Sign Up

Already a member? Sign in

Top Brokers

More Brokers

Market Data
News
Trading Tools
Markets
Discover

Hot Features

Follow Feed

Connect with traders and investors in our Follow Feed community.

Options Flow

Explore comprehensive options data and use advanced filters with Options Flow.

Monitor

Organize and monitor your stock and asset watchlist with Monitor.
Sign In Premium IconPremium Help Menu
FTSE 100
8,420.26
-0.22%
Dow Jones
40,003.59
0.34%
Gold vs US Dollar
2,413.935
0.00%
Brent Oil
83.76
0.00%
Bitcoin
67,082.92
0.00%
Pepperstone
Advertisement
Registration Strip Icon for alerts Register for real-time alerts, custom portfolio, and market movers
Get Started
  1. Home
  2. Investing
  3. Stocks
  4. USA
  5. NASDAQ
  6. Zevra Therapeutics Inc (ZVRA)

  7. Zevra Therapeutics Inc (ZVRA) News

Zevra Therapeutics (ZVRA)

Zevra Therapeutics Inc
Date:
Sort by:
 Showing the most relevant articles for your search:NASDAQ:ZVRA
DateTimeSourceHeadlineSymbolCompany
16/05/202402:31Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:ZVRAZevra Therapeutics Inc
16/05/202402:18Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:ZVRAZevra Therapeutics Inc
16/05/202402:15Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:ZVRAZevra Therapeutics Inc
16/05/202402:13Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:ZVRAZevra Therapeutics Inc
16/05/202402:05Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:ZVRAZevra Therapeutics Inc
13/05/202421:47Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:ZVRAZevra Therapeutics Inc
09/05/202421:34Edgar (US Regulatory)Form 10-Q - Quarterly report [Sections 13 or 15(d)]NASDAQ:ZVRAZevra Therapeutics Inc
09/05/202412:30GlobeNewswire Inc.Zevra Therapeutics to Participate at Upcoming Investor EventsNASDAQ:ZVRAZevra Therapeutics Inc
08/05/202412:54Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:ZVRAZevra Therapeutics Inc
08/05/202412:00GlobeNewswire Inc.Zevra Therapeutics Reports First Quarter 2024 Financial Results and Corporate UpdatesNASDAQ:ZVRAZevra Therapeutics Inc
01/05/202412:30GlobeNewswire Inc.Zevra Therapeutics to Report First Quarter 2024 Results on May 8, 2024NASDAQ:ZVRAZevra Therapeutics Inc
29/04/202412:30GlobeNewswire Inc.Zevra Therapeutics’ President and Chief Executive Officer Issues Letter to Stockholders Highlighting Recent Key Accomplishments and Outlook for 2024NASDAQ:ZVRAZevra Therapeutics Inc
15/04/202422:01GlobeNewswire Inc.Zevra Therapeutics Presents New Data on the Long-Term Safety and Efficacy of Arimoclomol as a Treatment for Niemann-Pick Disease Type C at the SIMD 45th Annual MeetingNASDAQ:ZVRAZevra Therapeutics Inc
10/04/202412:30GlobeNewswire Inc.Zevra Therapeutics Refinances Existing Debt with up to $100M in Committed Capital under New Credit FacilityNASDAQ:ZVRAZevra Therapeutics Inc
28/03/202420:32GlobeNewswire Inc.Zevra Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results and Corporate UpdatesNASDAQ:ZVRAZevra Therapeutics Inc
28/03/202411:42IH Market NewsUS Stock Futures Stable in Pre-Market On Path for Consecutive Quarterly Gains, Oil Prices RiseNASDAQ:ZVRAZevra Therapeutics Inc
26/03/202420:30GlobeNewswire Inc.Zevra Therapeutics Announces Top-Line Data from the Phase 2 Clinical Trial of KP1077 for Idiopathic HypersomniaNASDAQ:ZVRAZevra Therapeutics Inc
25/03/202420:30GlobeNewswire Inc.Zevra Therapeutics to Present at the 23rd Annual Needham Virtual Healthcare ConferenceNASDAQ:ZVRAZevra Therapeutics Inc
18/03/202411:30GlobeNewswire Inc.Zevra Therapeutics to Report 2023 Fourth Quarter and Full Year Financial Results on March 28, 2024NASDAQ:ZVRAZevra Therapeutics Inc
05/03/202412:34Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:ZVRAZevra Therapeutics Inc
04/03/202413:24Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:ZVRAZevra Therapeutics Inc
04/03/202412:30GlobeNewswire Inc.Zevra Therapeutics Provides FDA Update on the PDUFA Action Date for Arimoclomol as a Treatment for Niemann-Pick Disease Type CNASDAQ:ZVRAZevra Therapeutics Inc
28/02/202412:30GlobeNewswire Inc.Zevra Therapeutics to Participate at Upcoming Investor ConferencesNASDAQ:ZVRAZevra Therapeutics Inc
14/02/202421:51Edgar (US Regulatory)Form SC 13G - Statement of acquisition of beneficial ownership by individualsNASDAQ:ZVRAZevra Therapeutics Inc
06/02/202412:30GlobeNewswire Inc.Zevra Therapeutics to Present at the Oppenheimer 34th Annual Healthcare Life Sciences ConferenceNASDAQ:ZVRAZevra Therapeutics Inc
03/02/202402:22Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:ZVRAZevra Therapeutics Inc
03/02/202401:17Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:ZVRAZevra Therapeutics Inc
03/02/202401:14Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:ZVRAZevra Therapeutics Inc
03/02/202401:13Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:ZVRAZevra Therapeutics Inc
03/02/202401:11Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:ZVRAZevra Therapeutics Inc
 Showing the most relevant articles for your search:NASDAQ:ZVRA

Your Recent History

LSE
BX18
Citi Fun 25
BOV
PETR4
PETROBRAS PN
AMEX
HEQT
Simplify Hedged Equity ETF
NASDAQ
DUNEU
Dune Acquisition
LSE
VTI
Virotec
BIT
P1ZIT1
NLBNPIT1ZIT1 20240918 37...
LSE
ABF
Associated British Foods
LSE
FLX
Falanx
BIT
P1ZQV0
NLBNPIT1ZQV0 20241220 1000
BOV
OPSE3
Sudeste ON
UNSW3
GAIDENETH
Ninja Gaiden
COIN
KUMAUSD
LATK
GAZEETH
GazeTV
BIT
S29764
Societe Generale Effekten
LSE
HN78
Citi Fun 27
EU
VIRP
Virbac
Delayed Upgrade Clock
    ADVFN Logo

    United Kingdom
    Company
    Business
    Popular
    Get The App

    Support: +44 (0) 203 8794 460 | support@advfn.com

    By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions

    © 2024 ADVFN PLC - All Rights Reserved